Division of Hematology/Oncology

Faculty

faculty photo

Elizabeth Olson Hexner, M.D., M.S.T.R.

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215.614.1847
Fax: (215) 615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Post-Graduate Training
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Certifications
American Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Hematology), 2005.
American Board of Internal Medicine (Medical Oncology), 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Myeloproliferative Disorders
Umbilical Cord Blood Transplantation

Description of Clinical Expertise

Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Acute leukemia

Selected Publications

Bolanos-Meade, J., Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., Ho, V. T.: Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802. Blood 2014.

Hexner, E: Essential Thrombocythemia. Rare Disease Database, National Organization for Rare Diseases (NORD) 2014 Notes: https://www.rarediseases.org/rare-disease-information/rare-diseases/byID/577/viewFullReport.

Babushok, D., Hexner, E.: Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin Hematol 21(2): 114-22, 2014.

Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., Hexner, E., Zhang, Y.: Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. J Immunol 2014.

Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation. Br J Haematol 164: 83–93, 2014.

Reshef, R., Hexner, E. O., Loren, A. W., Frey, N. V., Stadtmauer, E. A., Luger, S. M., Mangan, J. K., Gill, S. I., Vassilev, P., Lafferty, K. A., Smith, J., Van Deerlin, V. M., Mick, R., Porter, D. L.: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2014.

Babushok, D. V., Cardamone, D., Rulander, N., Master, S. R., Hexner, E. O.: A Common, Under-Recognized Cause of Elevated Serum Erythropoietin. Am J Med 2014.

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013.

Lin, X., Rice, K. L., Buzzai, M., Hexner, E., Costa, F. F., Kilpivaara, O., Mullally, A., Soares, M. B., Ebert, B. L., Levine, R., Licht, J. D.: miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia 27: 344 - 52, 2013.

Kalota, A., Jeschke, G. R., Carroll, M., Hexner, E. O.: Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res 2013.

back to top
Last updated: 08/27/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter